Literature DB >> 283875

Relation of "lymphoid" phenotype and response to chemotherapy incorporating vincristine-prednisolone in the acute phase of Ph1 positive leukemia.

G Janossy, R K Woodruff, M J Pippard, G Prentice, A V Hoffbrand, A Paxton, T A Lister, C Bunch, M F Greaves.   

Abstract

Forty-four patients with Ph positive leukemia (36 developing blast crisis after chronic phase and eight presenting in acute leukemia) were classified into subgroups on the basis of reactivity of blasts with an anti-serum made against non-T,non-B acute lymphoid leukemia (ALL+), levels of terminal transferase enzyme (TdT+) and morphology. Positivity with anti-ALL serum was the most sensitive and reliable marker, and TdT was an important aid. The presence of "lymphoid" blasts in blast crisis of CML was related to the response to chemotherapy incorporating Vincristine and Prednisolone (VP). Patients with ALL+ blasts frequently (14 of 15 cases) responded to therapy while 21 of 25 patients who had no ALL+ blasts failed to respond. The clinical course of the ALL+ patients was variable: eight patients remitted with return to the appearances of the chronic phase; four patients demonstrated elimination of the Ph1 positive clone with hypoplasia and this was followed by normal (Ph1 negative) marrow regeneration in two. Subsequent relapse was of either the ALL+ "lymphoid" or the ALL-myeloid type. A regimen incorporating VP should be the treatment of choice in "lymphoid" blast crisis of CML.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 283875     DOI: 10.1002/1097-0142(197902)43:2<426::aid-cncr2820430204>3.0.co;2-h

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  14 in total

1.  Development of acute leukaemia after idiopathic myelofibrosis.

Authors:  J M Hernández; J F San Miguel; M González; A Orfao; M C Cañizo; C Bascones; J Hernández; A López Borrasca
Journal:  J Clin Pathol       Date:  1992-05       Impact factor: 3.411

2.  Chronic myelogenous leukemia--recent advances in treatment and pathogenesis.

Authors:  A B Deisseroth; S Purohit; A R Lopez
Journal:  West J Med       Date:  1986-03

Review 3.  Some aspects of immunological and cytochemical markers in leukemia.

Authors:  D Huhn
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

4.  Clonal origins of ETV6-RUNX1⁺ acute lymphoblastic leukemia: studies in monozygotic twins.

Authors:  D Alpar; D Wren; L Ermini; M B Mansur; F W van Delft; C M Bateman; I Titley; L Kearney; T Szczepanski; D Gonzalez; A M Ford; N E Potter; M Greaves
Journal:  Leukemia       Date:  2014-11-12       Impact factor: 11.528

5.  Glucocorticoid receptor level, terminal deoxynucleotidyl transferase activity and initial responsiveness to prednisone and vincristine in leukemia.

Authors:  A D Ho; S Stojakowits; H Pralle; M Dörner; W Hunstein
Journal:  Klin Wochenschr       Date:  1983-05-02

6.  Diagnostic specificity of the monoclonal anti-CALLA antibody VIL-A1 in leukemia and malignant lymphoma.

Authors:  W Knapp; D Lutz; P Bettelheim; T Radaszkiewicz; O Majdic; H Gadner
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

7.  Translocations (4p+; 6q-) and (12q-; Xp+) in blastic phase of a Ph1-positive chronic myeloid leukemia.

Authors:  S Suciu; E Marinca; F Bornuz; M Crisan; L Petrov; E Rădulescu
Journal:  Blut       Date:  1984-10

8.  Remission-induction of acute lymphoblastic transformation of chronic myeloid leukaemia, followed by long-term maintenance therapy.

Authors:  T de Witte; B de Pauw; C Haanen
Journal:  Blut       Date:  1986-04

9.  Myeloid dysplasia (MD): a hematological disorder preceding acute and chronic myeloid leukemia. A morphological study on sequential core biopsies of the bone marrow in 27 patients.

Authors:  J Thiele; K F Vykoupil; A Georgii
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1980

10.  Biochemical and immunological properties of human terminal deoxynucleotidyl transferase purified from blasts of acute lymphoblastic and chronic myelogenous leukemia.

Authors:  M R Deibel; M S Coleman; K Acree; J J Hutton
Journal:  J Clin Invest       Date:  1981-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.